StreetInsider.com News Articles

William Blair Starts Rhythm Pharmaceuticals (RYTM) at Outperform

Fri, 16 Oct 2026 03:11:54 -0400

William Blair analyst Alethia Young initiates coverage on Rhythm Pharmaceuticals (NASDAQ: RYTM) with a Outperform rating.

The analyst comments: “We are initiating coverage of Rhythm with an Outperform rating; our DCF-based valuation is $206 per share. Rhythm is a global, commercial-stage rare neuroendocrine company with an approved drug called Imcivree. Rhythm is building a pipeline around MC4R pathway-mediated diseases.

We are very bullish on its third commercial launch in acquired hypothalamic obesity (aHO) and believe this will be huge in the U.S., Japan, and Europe over time. The management team is an X factor as executives’ roots are as pioneers in commercializing

William Blair Starts Rhythm Pharmaceuticals (RYTM) at Outperform

Fri, 16 Oct 2026 03:11:54 -0400

William Blair analyst Alethia Young initiates coverage on Rhythm Pharmaceuticals (NASDAQ: RYTM) with a Outperform rating.

Rhythm Pharmaceuticals (RYTM) PT Lowered to $145 at JPMorgan

Thu, 15 Oct 2026 09:10:23 -0400

JPMorgan analyst Priyanka Grover lowered the price target on Rhythm Pharmaceuticals (NASDAQ: RYTM) to $145.00 (from $146.00) while maintaining a Overweight rating.

Rhythm Pharmaceuticals launches IMCIVREE in Japan for hypothalamic obesity

Tue, 13 Oct 2026 19:30:12 -0400

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) has launched IMCIVREE (setmelanotide) in Japan for the treatment of acquired hypothalamic obesity (HO), following the drug's inclusion on Japan's National Health Insurance drug price list.

The commercial launch follows approval by Japan's Ministry of Health, Labour and Welfare in August 2026. According to the company, IMCIVREE is the first approved therapy in Japan for acquired HO. Rhythm estimates that approximately 5,000 to 8,000 people in Japan are living with the condition.

The approval was supported by data from the Phase 3 TRANSCEND trial, which enrolled 142 patients with acquired HO, including 12 patients from a Japanese

Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Japan for Patients with Acquired Hypothalamic Obesity

Tue, 13 Oct 2026 19:30:00 -0400

-- Launch follows MHLW approval of IMCIVREE for acquired hypothalamic obesity and inclusion on Japan's National Health Insurance drug price list --

-- IMCIVREE is the first approved therapy in Japan for patients living with acquired hypothalamic obesity --

BOSTON, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced the commercial launch of IMCIVREE^® (setmelanotide) in Japan to treat patients living with acquired hypothalamic obesity (HO), following its inclusion on

Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Japan for Patients with Acquired Hypothalamic Obesity

Tue, 13 Oct 2026 19:30:00 -0400

-- Launch follows MHLW approval of IMCIVREE for acquired hypothalamic obesity and inclusion on Japan's National Health Insurance drug price list --

-- IMCIVREE is the first approved therapy in Japan for patients living with acquired hypothalamic obesity --

Form SCHEDULE 13G RHYTHM PHARMACEUTICALS, Filed by: JPMORGAN CHASE & CO

Tue, 13 Oct 2026 13:38:00 -0400

si-local-file:///var/storage/secattach/20261013/27180401.html

Rhythm Pharmaceuticals (RYTM) PT Raised to $130 at H.C. Wainwright

Mon, 12 Oct 2026 06:51:43 -0400

(Updated - October 12, 2026 6:51 AM EDT)

H.C. Wainwright analyst Raghuram Selvaraju raised the price target on Rhythm Pharmaceuticals (NASDAQ: RYTM) to $130.00 (from $105.00) while maintaining a Buy rating.

The analyst commented: "We remind investors that Japan’s Ministry of Health, Labour and Welfare (MHLW) granted marketing authorization to IMCIVREE (setmelanotide) to treat patients living with acquired hypothalamic obesity (HO) in late August 2026. IMCIVREE, a melanocortin-4 receptor (MC4R) agonist which received orphan drug designation by the MHLW in March 2025, is the first therapy approved in Japan to treat acquired HO. Rhythm currently expects to launch IMCIVREE before the end

Rhythm Pharmaceuticals (RYTM) PT Raised to $130 at H.C. Wainwright

Mon, 12 Oct 2026 06:51:43 -0400

(Updated - October 12, 2026 6:51 AM EDT)

H.C. Wainwright analyst Raghuram Selvaraju raised the price target on Rhythm Pharmaceuticals (NASDAQ: RYTM) to $130.00 (from $105.00) while maintaining a Buy rating.

Rhythm Pharmaceuticals (RYTM) PT Raised to $159 at RBC Capital

Thu, 08 Oct 2026 08:27:40 -0400

RBC Capital analyst Lisa Walter raised the price target on Rhythm Pharmaceuticals (NASDAQ: RYTM) to $159.00 (from $155.00) while maintaining a Outperform rating.

Health Canada approves Rhythm's Imcivree for hypothalamic obesity

Tue, 22 Sep 2026 08:02:58 -0400

Rhythm Pharmaceuticals (Nasdaq: RYTM) announced that Health Canada has approved Imcivree (setmelanotide) for weight management in adult and pediatric patients four years of age and older with acquired hypothalamic obesity (HO).

The approval adds an indication to Imcivree, which Health Canada first cleared in 2023 for weight management in patients six years and older with obesity due to Bardet-Biedl syndrome or certain genetically confirmed deficiencies.

The approval is based on the Phase 3 TRANSCEND trial involving 142 patients with acquired HO. The trial met its primary endpoint, showing an 18.8% placebo-adjusted reduction in body mass index. Results from the trial were published

Health Canada approves Rhythm's Imcivree for hypothalamic obesity

Tue, 22 Sep 2026 08:02:58 -0400

Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE® (setmelanotide) for Weight Management in Adult and Pediatric Patients 4 years of Age and Older with Acquired Hypothalamic Obesity

Tue, 22 Sep 2026 08:00:00 -0400

-- First targeted therapy approved in Canada for patients four years and older living with acquired hypothalamic obesity (HO) --

BOSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that Health Canada has approved IMCIVREE^® (setmelanotide) for the additional indication of weight management in adult and pediatric patients 4 years of age and older with acquired hypothalamic obesity (HO). IMCIVREE was first approved by Health Canada in 2023 for weight management in adult and pediatric patients 6

Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE® (setmelanotide) for Weight Management in Adult and Pediatric Patients 4 years of Age and Older with Acquired Hypothalamic Obesity

Tue, 22 Sep 2026 08:00:00 -0400

-- First targeted therapy approved in Canada for patients four years and older living with acquired hypothalamic obesity (HO) --

Form 4 RHYTHM PHARMACEUTICALS, For: Sep 14 Filed by: Meeker David P

Mon, 14 Sep 2026 19:37:00 -0400

si-local-file:///var/storage/secattach/20260914/27059709.html

Form 144 RHYTHM PHARMACEUTICALS, Filed by: Meeker David P

Mon, 14 Sep 2026 16:50:00 -0400

si-local-file:///var/storage/secattach/20260914/27059067.html

Leerink Assumes Rhythm Pharmaceuticals (RYTM) at Outperform

Mon, 14 Sep 2026 06:11:46 -0400

Leerink assumes coverage on Rhythm Pharmaceuticals (NASDAQ: RYTM) with a Outperform rating and a price target of $133.00.

For an analyst ratings summary and ratings history on Rhythm Pharmaceuticals click here. For more ratings news on Rhythm Pharmaceuticals click here.

Shares of Rhythm Pharmaceuticals closed at $104.71 yesterday.

KeyBanc Starts Rhythm Pharmaceuticals (RYTM) at Overweight

Mon, 14 Sep 2026 06:06:40 -0400

KeyBanc analyst Jackson Ader initiates coverage on Rhythm Pharmaceuticals (NASDAQ: RYTM) with a Overweight rating and a price target of $133.00.

For an analyst ratings summary and ratings history on Rhythm Pharmaceuticals click here. For more ratings news on Rhythm Pharmaceuticals click here.

Shares of Rhythm Pharmaceuticals closed at $104.71 yesterday.

Rhythm Pharmaceuticals Announces New Data Presentations at the European Society for Paediatric Endocrinology Meeting

Thu, 10 Sep 2026 08:00:00 -0400

-- Real-world data showed reductions in BMI with up to 18 months of setmelanotide therapy in 30 paediatric patients with acquired hypothalamic obesity (HO) in France –

-- Phase 3 analyses demonstrated improvements across multiple cardiometabolic risk indices with setmelanotide in acquired HO --

BOSTON, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced Rhythm and its collaborators will present three posters and three oral presentations relating to the company’s work in rare melanocortin-4

Rhythm Pharmaceuticals Announces New Data Presentations at the European Society for Paediatric Endocrinology Meeting

Thu, 10 Sep 2026 08:00:00 -0400

-- Real-world data showed reductions in BMI with up to 18 months of setmelanotide therapy in 30 paediatric patients with acquired hypothalamic obesity (HO) in France –

-- Phase 3 analyses demonstrated improvements across multiple cardiometabolic risk indices with setmelanotide in acquired HO --

Deutsche Bank Starts Rhythm Pharmaceuticals (RYTM) at Hold

Thu, 27 Aug 2026 16:36:27 -0400

Deutsche Bank analyst David Hoang initiates coverage on Rhythm Pharmaceuticals (NASDAQ: RYTM) with a Hold rating and a price target of $120.00.

For an analyst ratings summary and ratings history on Rhythm Pharmaceuticals click here. For more ratings news on Rhythm Pharmaceuticals click here.

Shares of Rhythm Pharmaceuticals closed at $111.87 yesterday.

Rhythm gets Japan approval for obesity drug Imcivree

Mon, 24 Aug 2026 08:03:23 -0400

Rhythm Pharmaceuticals (Nasdaq: RYTM) announced that Japan's Ministry of Health, Labour and Welfare has granted marketing authorization to Imcivree (setmelanotide) for the treatment of acquired hypothalamic obesity, according to a company statement.

Imcivree, a melanocortin-4 receptor agonist, is described by Rhythm as the first therapy approved in Japan for this condition. The company estimates between 5,000 and 8,000 people in Japan are living with acquired hypothalamic obesity, a rare disease characterized by accelerated and sustained weight gain caused by injury to the hypothalamus.

Rhythm expects to commercially launch Imcivree in Japan before the end of 2026, pending final pricing determination.

The approval is

Rhythm gets Japan approval for obesity drug Imcivree

Mon, 24 Aug 2026 08:03:23 -0400

Rhythm expects to commercially launch Imcivree in Japan before the end of 2026, pending final pricing determination.

The approval is

Rhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity (HO) in Japan

Mon, 24 Aug 2026 08:00:00 -0400

-- Approximately 5,000 to 8,000 patients estimated to be living with acquired HO in Japan --

-- Commercial launch in Japan expected by end of 2026, pending final pricing determination --

BOSTON, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted marketing authorization to IMCIVREE^® (setmelanotide) to treat patients living with acquired hypothalamic obesity (HO).

IMCIVREE, a melanocortin-4 receptor (MC4R) agonist which received

Rhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity (HO) in Japan

Mon, 24 Aug 2026 08:00:00 -0400

-- Approximately 5,000 to 8,000 patients estimated to be living with acquired HO in Japan --

-- Commercial launch in Japan expected by end of 2026, pending final pricing determination --

IMCIVREE, a melanocortin-4 receptor (MC4R) agonist which received